Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE2V.L Regulatory News (E2V)

  • There is currently no data for E2V

Contract Win

20 Nov 2008 07:00

RNS Number : 5213I
e2v technologies PLC
20 November 2008
 



20 November  2008 

e2v technologies plc

Contract Win 

e2v technologies, a specialist developer and manufacturer of high technology components and sub-systems, announces an £11m contract renewal to supply Varian Medical Systems, Inc., headquartered in Palo Alto, US, with electron devices for incorporation into linear accelerators, for use in radiotherapy cancer treatment and cargo screening systems.

The contract will be worth at least £11m (payments will be in US dollars at the prevailing exchange rate) over two years, and is the first of a number of anticipated multi-year contract renewals for electron devices used in linear accelerators. e2v's products generate and deliver the microwave power required from the linear accelerator to produce X-rays used in both the imaging and radiation treatment of tumours as well as the imaging systems within cargo screening equipment.

This contract represents an increase in business with this customer, has the potential to increase in value over the term of the agreement, and is in line with management's growth expectations for this sector.

Keith Attwood, Chief Executive of e2v said: ``This multi-year contract renewal with Varian is a demonstration of the strong and close relationships we build with our strategic partners.''

For further information:

e2v technologies plc

Tel: +44 (0)1245 493493

Keith Attwood/Mike Hannant

www.e2v.com

Financial Dynamics

Tel: +44 (0)20 7269 7225

Jon Simmons/Sophie Kernon

   

NOTES FOR EDITORS

e2v 

e2v's objective is to be a global leader in the design and supply of specialised components and sub-systems that enable the world's leading systems companies to deliver innovative solutions for medical and science, aerospace and defence, and commercial and industrial markets.

e2v has 4 major product groups:

High performance electron devices and subsystems for applications including defence electronic countermeasures, radiotherapy cancer treatment, and radar systems

Advanced Imaging sensors and cameras for applications including industrial process control, dental X-ray systems, space science and life sciences

Specialist semiconductors, including logic, memory and microprocessors for high reliability mission-critical programs in avionics, defence and telecommunications, sensor data acquisition, and high speed data conversion

A range of professional sensing products for applications including fire, rescue and security thermal imaging, X-ray spectroscopy, and military surveillance, targeting and guidance

For the year ended 31 March 2008, e2v achieved sales of £205m and is listed on the London Stock Exchange. In October 2008 e2v acquired QP semiconductor, a leading US-based designer and supplier of specialty semiconductor components used in military and aerospace applications, establishing e2v's first US manufacturing base. 

The Company is headquartered in the United Kingdom and has approximately 1800 employees in six production facilities across Europe and North America. e2v also operates a global network of sales and technical support offices, supported by local distributors and resellers.

Further information is available from www.e2v.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTFKCKDABDDFDD
Date   Source Headline
29th Nov 20123:17 pmRNSHolding(s) in Company
23rd Nov 201211:15 amRNSHolding(s) in Company
23rd Nov 201211:15 amRNSHolding(s) in Company
20th Nov 20124:45 pmRNSNotification of Major Interest in Shares
20th Nov 201210:40 amRNSHolding(s) in Company
19th Nov 20129:00 amRNSHolding(s) in Company
15th Nov 201210:25 amRNSTotal Voting Rights
12th Nov 20124:40 pmRNSSecond Price Monitoring Extn
12th Nov 20124:35 pmRNSPrice Monitoring Extension
12th Nov 20123:21 pmRNSHolding(s) in Company
12th Nov 201211:30 amRNSHolding(s) in Company
5th Nov 20127:00 amRNSHalf-year results for six months to 30 September
1st Nov 20123:59 pmRNSDirector/PDMR Shareholding
11th Oct 20127:00 amRNSPeriod End Update
2nd Oct 20122:30 pmRNSHolding(s) in Company
26th Sep 20125:00 pmRNSAdditional Listing Announcement - Amendment
25th Sep 201210:00 amRNSTotal Voting Rights
21st Sep 20124:49 pmRNSAdditional Listings Announcement
13th Sep 20124:49 pmRNSShare Buy-back Programme Update
25th Jul 201212:12 pmRNSAGM - notification of proxy votes
25th Jul 20127:00 amRNSInterim Management Statement
10th Jul 201212:30 pmRNSTotal Voting Rights
3rd Jul 20124:30 pmRNSAwards under Long Term Incentive Plan
29th Jun 201210:21 amRNSAwards under Deferred Bonus Plan
18th Jun 201211:15 amRNSTotal Voting Rights
24th May 20123:30 pmRNSBlock Listing Return
22nd May 20123:15 pmRNSTotal Voting Rights
22nd May 20123:15 pmRNSDirector/PDMR Shareholding
21st May 20129:42 amRNSFinal Dividend Timetable
21st May 20127:00 amRNSResults for the year ended 31 March 2012
16th May 20127:00 amRNSSale of non-core businesses
15th May 201210:30 amRNSTotal Voting Rights
19th Apr 20127:00 amRNSYear end trading update
1st Mar 201211:20 amRNSTotal Voting Rights
27th Feb 20122:36 pmRNSHolding(s) in Company
27th Feb 201212:39 pmRNSHolding(s) in Company
20th Feb 20127:00 amRNSMemorandum of Understanding with Rio Tinto
1st Feb 201210:45 amRNSTotal Voting Rights
30th Jan 20127:00 amRNSInterim Management Statement
5th Jan 20123:41 pmRNSTotal Voting Rights
22nd Dec 201110:56 amRNSTotal Voting Rights
19th Dec 20117:16 amRNSShare Buyback
1st Dec 20113:56 pmRNSTotal Voting Rights
18th Nov 201112:44 pmRNSDirector/PDMR Shareholding
14th Nov 20117:00 amRNSHalf Yearly Report
13th Oct 20117:00 amRNSPeriod end update
6th Oct 20115:57 pmRNSAnnouncement Released In Error
6th Oct 20115:20 pmRNSHolding(s) in Company
6th Oct 20115:15 pmRNSHolding(s) in Company
3rd Oct 201112:44 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.